What is IMLYGIC used for?
What is IMLYGIC used for?
This medication is used to treat a certain type of skin cancer (melanoma). It contains a live virus (cold sore virus) that has been weakened. Talimogene laherparepvec infects the cancer cells and works by slowing or stopping their growth.
What type of medications may diminish the therapeutic effect of Talimogene Laherparepvec IMLYGIC and should therefore be avoided by patients taking the drug?
IMLYGIC is sensitive to acyclovir. Acyclovir or other antiviral agents may interfere with the effectiveness of IMLYGIC. Therefore, consider the risks and benefits of IMLYGIC treatment before administering antiviral agents to manage herpetic infection.
How much does IMLYGIC cost?
The cost for Imlygic injectable suspension (1 mpfu/mL) is around $67 for a supply of 1 milliliter(s), depending on the pharmacy you visit….Injectable Suspension.
| Quantity | Per unit | Price |
|---|---|---|
| 1 milliliter | $5,736.25 | $5,736.25 |
Is IMLYGIC a biologic?
27, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration ( FDA ) has approved the Biologics License Application for IMLYGIC™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous.
What is Talimogene Laherparepvec used for?
Talimogene laherparepvec is a genetically modified weak form of type 1 herpes simplex virus (the virus that causes common cold sores). Talimogene laherparepvec is used to treat a type of cancer called melanoma when it is on the skin or in the lymph glands.
How does Talimogene Laherparepvec work?
How Does T-VEC (Imlygic) Work? Your physician injects T-VEC directly into melanoma tumors. The virus then replicates within the cells, causing them to rupture and die. T-VEC is a local treatment, which means that it is applied directly to melanoma lesions to treat those cells.
How much does Talimogene Laherparepvec cost?
The company says the treatment will cost an average of $65,000. An approach deemed novel by the Center for Biologics and Drug Evaluation at the FDA, Imlygic (talimogene laherparepvec ot T-Vec)—an oncolytic virus therapy—was granted approval by the FDA close on the heels of the support in Europe.
How is TCC administered?
T-VEC is injected directly into the melanoma lesions. The second treatment must be administered three weeks after the initial injection. Patients receive subsequent doses every two-three weeks for six months or, for as long as you have tumors.
What class of drug is Talimogene Laherparepvec?
Talimogene laherparepvec is in a class of medications called oncolytic viruses. It is a weakened and changed form of Herpes Simplex Virus Type I (HSV-1 ‘cold sore virus’) that works by helping to kill cancer cells.
When was Imlygic FDA approved?
Development Timeline for Imlygic
| Date | Article |
|---|---|
| Oct 27, 2015 | Approval FDA Approves Imlygic (talimogene laherparepvec) for the Treatment of Melanoma |